British Columbia Expands ADHD Treatment Coverage with FOQUEST® Addition

On July 23, 2025, British Columbia officially announced the inclusion of FOQUEST® (methylphenidate hydrochloride controlled-release capsules) in its PharmaCare formulary, making it eligible for reimbursement under public drug plans. This significant move aligns British Columbia with other provinces across Canada that have already integrated FOQUEST® into their public drug coverage, thereby enhancing access to treatment for Attention Deficit Hyperactivity Disorder (ADHD) for patients aged six years and older.

The addition of FOQUEST® marks a crucial advancement in ADHD treatment accessibility, as stated by Juanita Beaudry, Executive Director of the Centre for ADHD Awareness Canada (CADDAC). "Public funding in British Columbia ensures equitable access to ADHD treatments in BC," Beaudry emphasized, highlighting the importance of this decision for patients and healthcare providers alike. Prior to this, similar approvals had occurred in provinces such as Alberta, Manitoba, Ontario, and Quebec, along with coverage for First Nations and other federal programs.

Elvium Life Sciences, the pharmaceutical company behind FOQUEST®, expressed satisfaction with this development. Jodan Ratz, Country Medical Director at Elvium Life Sciences, remarked, "We thank the province for its decision which now means that all ADHD patients aged six years and older have equivalent access to FOQUEST® should this be the right treatment for them." This unification of coverage promises to streamline treatment options for ADHD across the nation.

FOQUEST® is a long-acting, once-daily capsule designed to manage ADHD symptoms effectively. The maximum dosage is 70mg for children and adolescents, and 100mg for adults. However, it is essential to note that the medication carries a Serious Warning regarding potential abuse and dependence, necessitating careful consideration by healthcare professionals when prescribing. Adverse effects commonly associated with methylphenidate include headache, insomnia, decreased appetite, and abdominal pain, most of which are mild to moderate in severity.

The decision to include FOQUEST® in the British Columbia PharmaCare formulary reflects a broader commitment to addressing mental health needs within the province. This initiative may serve as a model for other regions, reinforcing the importance of accessible treatment options for managing ADHD. As the public health landscape continues to evolve, the implications of this approval could lead to increased awareness and advocacy for mental health resources in Canada.

In summary, the integration of FOQUEST® into British Columbia's public drug plan is a pivotal step towards improved access to ADHD treatments across Canada, ensuring that patients receive the necessary support and care to manage their conditions effectively. Looking ahead, stakeholders will need to monitor the impact of this change on patient outcomes and overall public health in the province and beyond.